Long-Acting Injectable Cabotegravir for HIV Prevention: Promises and Pitfalls

Presentation

Raphael J. Landovitz, MD, MSc, Professor of Medicine, Division of Infectious Diseases, David Geffen School of Medicine

Two recent landmark HIV Prevention Trials Network (HPTN) studies demonstrated the efficacy of long-acting, injectable cabotegravir (CAB-LA) as pre-exposure prophylaxis (PrEP) against HIV. These studies showed that CAB-LA injected once every eight weeks was superior to daily oral tenofovir/emtricitabine for PrEP among cisgender men and transgender women who have sex with men (HPTN 083) and cisgender women (HPTN 084). Both studies demonstrated that CAB-LA was well-tolerated, offering a new and important PrEP option for individuals at risk for HIV infection.

As regulatory approvals for CAB-LA move forward, Raphael J. Landovitz, MD, MSc, the HPTN 03 Protocol chair, will discuss findings from the randomized controlled trial and ongoing open-label extension phases of the studies, including some thoughts on opportunities and challenges of clinical implementation in this grand rounds.

Raphael Landovitz, MD, MSc, is a professor of Medicine in the Division of Infectious Diseases at the David Geffen School of Medicine and director of the UCLA Center for Clinical AIDS Research & Education. He leads several biomedical and behavioral prevention intervention studies and projects using Post-Exposure Prophylaxis (PEP) and Pre-Exposure Prophylaxis (PrEP) strategies for men who have sex with men and cis- and transgender women. He was the principal investigator of two multisite PrEP demonstration projects in Los Angeles County. In addition, he led the NIH/DAIDS-funded Phase 2 and Phase 3 registrational clinical trials evaluating long-acting injectable cabotegravir for PrEP, contributing to recent US FDA approval. He is currently evaluating the implementation of long-acting injectable PrEP and continuing to study other investigational long-acting/extended-release products for HIV prevention.

Register here